PRESS RELEASE
8 December 2021

She Didn’t Need To Be Commissioner: Janet Woodcock’s Transformative Legacy

MF
Morrison & Foerster LLP

Contributor

Known for providing cutting-edge legal advice on matters that are redefining industries, Morrison & Foerster has 17 offices located in the United States, Asia, and Europe. Our clients include Fortune 100 companies, leading tech and life sciences companies, and some of the largest financial institutions. We also represent investment funds and startups.
Stacy Cline Amin spoke to The Pink Sheet about Janet Woodcock, who is expected to scale back her role at the U.S. Food and Drug Administration (FDA) following 35 years of service.
United States

Stacy Cline Amin spoke to The Pink Sheet about Janet Woodcock, who is expected to scale back her role at the U.S. Food and Drug Administration (FDA) following 35 years of service.

According to Stacy, who served as FDA chief counsel from 2018 to 2021 and also interacted with Woodcock in other government roles, Janet "was in command of the room because she was always the most knowledgeable person in the room, she had the best grasp of the facts."

"Nobody told her what to do...even the Secretary wouldn't try to tell Janet Woodcock what to do," Stacy added. "It was always more of a conversation with her or a negotiation with her. She could really see the big picture and was great at shaping reasonable outcomes to challenging situations."

Read the full article (subscription required).

Contributor

Known for providing cutting-edge legal advice on matters that are redefining industries, Morrison & Foerster has 17 offices located in the United States, Asia, and Europe. Our clients include Fortune 100 companies, leading tech and life sciences companies, and some of the largest financial institutions. We also represent investment funds and startups.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More